Opening book details…
Can I read Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report on EtoBox?
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report by Lucia Leccisotti; Francesca Cinti; Gian Pio Sorice; Domenico D’Amario; Margherita Lorusso; Maria Angela Guzzardi; Teresa Mezza; Shawn Gugliandolo; Camilla Cocchi; Umberto Capece; Luca Indovina; Pietro Manuel Ferraro; Patricia Iozzo; Filippo Crea; Alessandro Giordano; Andrea Giaccari is a Medicine article available to read on EtoBox.
What is Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report about?
## Abstract ## Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates for heart failure (HF). However, the mechanisms behind these benefits are not fully understood. This study was performed to investigate the effects of the SGLT-2i dapagliflozin on myocardial perfusion and glucose metabolism in patients with T2D and stable coronary artery disease (coronary stenosis ≥ 30% and 6 months) but no HF. ## Methods This was a single-center, prospective, randomized, double-blind, controlled clinical trial including 16 patients with T2D randomized to SGLT-2i dapagliflozin (10 mg daily) or placebo. The primary outcome was to detect changes in myocardial glucose uptake (MGU) from baseline to 4 weeks after treatment initiation by [(18)F]2-deoxy-2-fluoro-D-glucose (FDG) PET/CT during hyperinsulinemic euglycemic clamp. The main secondary outcome was to assess whether the hypothetical changes in MGU were associated with changes in myocardial blood flow (MBF) and myocardial flow reserve (MFR) measured by ^13^N-ammonia PET/CT. The study
Who reads Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Lucia Leccisotti; Francesca Cinti; Gian Pio Sorice; Domenico D’Amario; Margherita Lorusso; Maria Angela Guzzardi; Teresa Mezza; Shawn Gugliandolo; Camilla Cocchi; Umberto Capece; Luca Indovina; Pietro Manuel Ferraro; Patricia Iozzo; Filippo Crea; Alessandro Giordano; Andrea Giaccari
- Publisher
- Springer Science and Business Media LLC
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)